The largest database of trusted experimental protocols
> Living Beings > Bacterium > Campylobacter jejuni

Campylobacter jejuni

Campylobacter jejuni is a spiral-shaped, microaerophilic, gram-negative bacterium that is a leading cause of gastroenteritis worldwide.
It is commonly found in the gastrointestinal tract of many animals, including poultry, cattle, and wild birds.
Infection with C. jejuni can lead to diarrhea, abdominal pain, and fever, and in some cases, can trigger the development of Guillain-Barré syndrome, a rare neurological disorder.
Researching effective protocols and methods for the detection, identification, and management of C. jejuni is crucial for public health and food safety.
PubCompare.ai offers a powerful tool to streamline this research by leveraging AI-driven protocol comparisons, helping scientists identify the most reproducible and accurate approaches from literature, pre-prints, and patents.

Most cited protocols related to «Campylobacter jejuni»

ResFinder 4.0 was validated with datasets consisting of MIC values (BMD or Etest, Table 1) and WGS data (Illumina sequencing) of Escherichia coli, Salmonella spp., Campylobacter jejuni, E. faecium, E. faecalis and S. aureus of different origins (Table 1). These datasets represent a convenience sample. Phenotypic AST results were interpreted using the EUCAST epidemiological cut-off values (ECOFFs) to categorize isolates as WT (MIC ≤ECOFF) and non-WT (MIC >ECOFF) (www.eucast.org). Exceptions were: (i) one S. aureus dataset for which phenotypic AST was performed by disc diffusion and interpreted by EUCAST clinical breakpoints (Table 1); and (ii) one E. coli dataset that consisted of Illumina WGS data only and MIC values were available for the data provider but not for the ResFinder 4.0 developers, thus providing a blind test of the tool performance (Table 1). WGS data were obtained as raw reads and processed through a quality control (QC) pipeline as described here: https://bitbucket.org/genomicepidemiology/foodqcpipeline/. In brief, reads were trimmed using bbduk2 (https://jgi.doe.gov/data-and-tools/bbtools/) to a phred score of 20, reads less than 50 bp were discarded, adapters were trimmed away and a draft de novo assembly was created using SPAdes.21 (link) From the assemblies, contigs below 500 bp were discarded. The most important parameters that were used to assess quality of sequencing data were: number of bases left after trimming, N50, number of contigs and total size of assembly. QC parameters used as guidelines were: read depth of at least 25×, N50 of >30 000 bp and a limit on the number of contigs to <500.
WGS data (FASTQ) were used as input for ResFinder 4.0 using default parameters (≥80% identity over ≥60% of the length of the target gene) and also for SNP-based phylogenetic analysis as previously described22 (link) to verify the genetic diversity of the validation datasets. SNP analysis was not performed for the Salmonella spp. dataset whose diversity was already described previously.23 (link) The ResFinder 4.0 output was analysed to define AMR genotypes, i.e. patterns of resistance determinants observed for each antimicrobial, in each dataset.
Genotype–phenotype concordance was defined as presence or absence of a genetic determinant of resistance to a specific antimicrobial agent in non-WT (nWT) or WT isolates, respectively. Genotype–phenotype discordance was defined either as presence of a relevant AMR determinant in WT isolates or as absence of a relevant AMR determinant in nWT isolates. All discordances were individually analysed.
Sequence data that did not derive from previous studies (Table 1) have been deposited at NCBI (E. coli dataset from Germany: PRJNA616452; E. faecium dataset from Germany: PRJNA625631; E. faecium dataset from Belgium: PRJNA552025; S. aureus dataset from Belgium: PRJNA615176) and in the European Nucleotide Archive (S. aureus dataset from Denmark: PRJEB37586).
Publication 2020
Campylobacter jejuni Diffusion Epsilometer Test Escherichia coli Europeans Fibrinogen Genetic Diversity Genotype Microbicides Nucleotides Phenotype Reproduction R Factors Salmonella Staphylococcus aureus Visually Impaired Persons
For evaluation of assay performance, genomic materials or reference strains were obtained from American Tissue and Culture Collection (ATCC, Manassas, VA) or BEI resources for adenovirus 1, 5, 40 and 41, human cytomegalovirus, enterovirus 71, Epstein-Barr virus, Aeromonas hydrophila, Bacteroides fragilis, Campylobacter coli, Campylobacter upsalensis, Campylobacter hyointestinalis, Campylobacter jejuni, Helicobacter pylori, Listeria monocytogenes, Mycobacterium tuberculosis, Plesiomonas shigelloides, Salmonella enterica, Vibrio parahaemolyticus, Yersinia enterocolitica, Blastocystis hominis, Cryptosporidium hominis, Cryptosporidium meleagridis, Schistosoma mansoni. Cryptosporidium parvum and Encephalitozoon intestinalis were purchased from Waterborne Inc. (New Orleans, LA). PCR amplicons were generated from the relevant positive clinical samples for Ancyclostoma duodenale, Necator americanus, Strongyloides stercoralis, Cyclospora cayetanensis, Cystoisospora belli, and Enterocytozoon bieneusi. For comparison between stool and swab (FLOQSwabs; Copan Italia, Brescia, Italy), 129 consecutive swab samples were collected from children under five admitted for acute diarrhea in Haydom Lutheran Hospital, Tanzania. A matched stool sample from the same patient was obtained as soon as feasible within the same day. Raw stool samples were transported with a cold chain to the lab within 6 hours and stored at -80°C until testing. Swabs were stored at room temperature until testing. For comparison between different extraction methods and validation of the newly developed qPCR assays on clinical samples, we chose 246 archived stool samples collected in Tanzania, Bangladesh, Nepal, Pakistan, and India through the MAL-ED project (the Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development [6 (link)]) in order to obtain specimens positive for 30 diverse enteropathogens. All sites including Haydom Global Health Institute, Tanzania, Aga Khan University, Pakistan, Armed Forces Research Institute of Medical Sciences, Thailand, International Centre for Diarrhoeal Disease Research, Bangladesh, Christian Medical College, India, received ethical approval from their respective governmental, local institutional, and collaborating institutional ethics review boards. Written informed consent was obtained from the parent or guardian of every child.
Full text: Click here
Publication 2016
Adenovirus Infections Aeromonas hydrophila Bacteroides fragilis Biological Assay Blastocystis hominis Campylobacter Campylobacter coli Campylobacter hyointestinalis Campylobacter jejuni Child Children's Health Cryptosporidium Cryptosporidium parvum Cyclospora Diarrhea Encephalitozoon intestinalis Enterocytozoon bieneusi Enterovirus Infections Epstein-Barr Virus Feces Genome Helicobacter pylori Human Herpesvirus 5 Infection Legal Guardians Listeria monocytogenes Malnutrition Military Personnel Mycobacterium tuberculosis Necator americanus Parent Patients Plesiomonas shigelloides Salmonella enterica Schistosoma mansoni Strains Strongyloides stercoralis Tissues Vibrio parahaemolyticus Yersinia enterocolitica
Information regarding mutations in chromosomal genes associated with antimicrobial resistance was collected from published papers (Table 1). The reference sequences were selected from WT Escherichia coli strain K-12 (MG1655) for the E. coli database, Salmonella Typhimurium strain LT2 for the Salmonella enterica database and Campylobacter jejuni NCTC 11168 for the C. jejuni database.

Overview of chromosomal point mutations for each species included in the database

SpeciesGeneChromosomal mutationsResistanceReference(s)
E. coligyrAA51V, A67S, G81C, D82G, S83L, S83W, S83A, S83V, S83I, A84P, A84V, D87N, D87G, D87Y, D87H, D87V, Q106H, Q106R, A196Equinolone4 (link)
gyrBR136L, R136C, R136H, R136S, R136G, R136I, R136E, D426N, K447Equinolone4 (link),5 (link)
parCA56T, S57T, F60I, F60L, G78D, G78K, S80R, S80I, S80L, S80Y, S80F, E84G, E84K, E84V, E84A, A108V, A108Tquinolone4 (link),6 (link),7 (link)
parEL416F, G423R, P439S, I444F, S458T, E460D, E460K, I464F, I470M, D475E, D476N, I529Lquinolone4 (link),6 (link),7 (link)
pmrAS39I, R81Scolistin8 (link)
pmrBV161Gcolistin8 (link)
folPP63R, P64L, P64S, P64A, P64Hsulphonamides9 (link)
rpoBV146F, Q513L, Q513P, H526Y, R529C, R529S, S531F, L533P, T563P, P564L, R687Hrifamycin10 (link)
23SaA2059Gmacrolide11 (link)
16S rrsBaA523C, G527T, C528T, G1064T, G1064C, G1064A, C1066T, G1068Aspectinomycin12–15 (link)
16S rrsBaA964G, G1053A, C1054T, A1055G, G1058Ctetracycline13 (link),16 (link)
16S rrsBaT1406A, A1408Ggentamicin17 (link)
16S rrsCaA794G, A794T, G926A, G926T, G926C, A1519G, A1519C, A1519Tkasugamycin18 (link)
16S rrsHaC1192Tspectinomycin19 (link)
S. entericagyrAA67P, D72G, V73I, G81C, G81S, G81H, G81D, D82G, D82N, S83Y, S83F, S83A, D87N, D87G, D87Y, D87K, L98V, A119S, A119E, A119V, A131G, E139Aquinolone4 (link)
gyrBY421C, R438L, S464Y, S464F, E466Dquinolone4 (link),20 (link)
parCT66I, G78D, S80R, S80I, E84K, E84Gquinolone4 (link),21 (link)
parEM438I, E454G, S458P, V461G, H462Y, A499T, V514G, V521Fquinolone4 (link),20 (link),22 (link)
pmrAG15R, G53E, G53R, R81C, R81Hcolistin23 (link)
pmrBL22P, S29R, T92A, P94Q, E121A, S124P, N130Y, T147P, R155P, T156P, T156M, V161M, V161L, V161G, E166K, M186I, G206W, G206R, S305Rcolistin23 (link)
16S rrsDaC1065T, C1192Tspectinomycin24 (link)
C. jejunigyrAA70T, D85T, T86I, T86A, T86K, T86V, D90A, D90N, D90T, P104Squinolone25–28 (link)
23SaA2074G, A2074T, A2074C, A2075Gmacrolide28 (link)
cmeRA86Gmacrolide29 (link)
rplVA103Cmacrolide29 (link)
rpsLK88E, K88R, K88Qspectinomycin30 (link)

rRNA gene, mutation shown in DNA.

Publication 2017
Campylobacter jejuni Chromosomes Escherichia coli Genes Microbicides Mutation Point Mutation Salmonella typhimurium LT2 Strains
We used PanACoTA48 version 1.2.0 to build phylogenies for 15 bacterial species (Escherichia coli, Pseudomonas aeruginosa, Streptococcus pyogenes, Salmonella enterica, Listeria monocytogenes, Helicobacter pylori, Mycobacterium tuberculosis, Neisseria meningitidis, Staphylococcus aureus, Bacillus subtilis, Campylobacter jejuni, Klebsiella pneumoniae, Bacillus velezensis, Acinetobacter baumannii, Enterococcus faecium). PanACoTA allows phylogenetic tree reconstructions based on the core genomes. For each of the species, we took all genomes under a nucleic acid format in NCBI (fna) and annotated them using prodigal (PanACoTA annotate options–cutn 10000–l90 400 –prodigal). We then computed the pangenome and coregenome (PanACoTA pangenome; PanACoTA corepers; with default parameters). Finally, we aligned the coregenome (PanACoTA align, default parameters) and computed a phylogenetic tree (PanACoTA tree, -b 1000). For this step PanACoTA, uses IQTree49 (link), (version 2.1.4) and the following option (iqtree -m GTR -bb1000 -st DNA).
Full text: Click here
Publication 2022
Acinetobacter calcoaceticus Bacillus subtilis Bacillus velezensis Bacteria Campylobacter jejuni Enterococcus faecium Escherichia coli Genome Helicobacter pylori Klebsiella pneumoniae Listeria monocytogenes Mycobacterium tuberculosis Neisseria meningitidis Nucleic Acids Pseudomonas aeruginosa Reconstructive Surgical Procedures Salmonella enterica Staphylococcus aureus Streptococcus pyogenes Trees

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2011
Abscess Animals Antibiotics Bacteriocins BLOOD Campylobacter jejuni Cardiac Arrest Cecum CFC1 protein, human Ciprofloxacin Colon Escherichia coli Formalin FRAP1 protein, human Gentamicin Goblet Cells Hyperplasia IL10 protein, human Infection Inflammation Institutional Animal Care and Use Committees Intestines Lamina Propria Mesentery Mus Nodes, Lymph Paraffin Proteins Salmonella typhimurium Sirolimus Specific Pathogen Free Spleen Strains Streptomycin Ulcer

Most recents protocols related to «Campylobacter jejuni»

The subcohort also collects monthly saliva swab samples over the 1-year period. Families are directed to rub an Oracol sponge swab (Malvern Medical Developments, Worcester, UK) along the gum of their child. Swabs are stored in participants’ freezers (−20°C) until they are ready to be shipped with stools. Swabs are shipped to Temple University where staff recover saliva from swabs using centrifugation.39 40 (link) Saliva samples are stored at −80°C until analysis using multiplex fluorescent microsphere immunoassays using the Luminex xMAP platform (Luminex, Austin, Texas, USA) to quantify IgG responses to specific antigens. Microsphere sets with distinct fluorescence are coupled with target proteins to allow for simultaneous detection of antibodies to multiple targets in samples. Saliva samples are analysed for IgG responses to common waterborne pathogens, including noroviruses GI and GII, Campylobacter jejuni and Cryptosporidium.39–41 (link)
Publication 2023
Antibodies Antigens austin Campylobacter jejuni Centrifugation Child Cryptosporidium Feces Fluorescence Immunoassay Microspheres Norovirus pathogenesis Porifera Protein Targeting, Cellular Saliva
EU MSs reported mandatory data collected following AMR monitoring programs during 2020 and 2021. ‘Directive 2003/99/EC requires Member States to ensure that monitoring provides comparable data on the occurrence of antimicrobial resistance (‘AMR’) in zoonotic agents and, in so far as they present a threat to public health, other agents’. ‘Directive 2003/99/EC also requires Member States to assess the trends and sources of AMR in their territory and to transmit a report every year covering data collected in accordance with that Directive to the Commission.’ Furthermore, some non‐EU countries reported AMR data and both, some EU and non‐EU reporting countries (RCs) also reported voluntary data from samples that were not included in the mandatory programs per reporting year.
The Commission Implementing Decision 2013/652/EU30 lays down detailed rules for the harmonised monitoring and reporting of AMR in zoonotic and commensal bacteria applicable until 31 December 2020. The Commission Implementing Decision (EU) 2020/172931 of 17 November 2020 lays down new rules for antimicrobial resistance monitoring performed in 2021 onwards. This Decision specifies harmonised rules for the period 2021–2027 for the monitoring and reporting of AMR to be carried out by Member States in accordance with EU Regulations.
The Commission Implementing Decision (EU) 2020/1729 determines specific technical requirements for AMR testing and reporting in relation to sampling in food‐producing animals and derived meat (at retail and at border control posts). The Commission Implementing Decision (EU) 2020/1729 indicates that the monitoring and reporting of AMR shall cover the following bacteria: (a) Salmonella spp.; (b) Campylobacter coli (C. coli); (c) Campylobacter jejuni (C. jejuni); (d) Indicator commensal Escherichia coli (E. coli); (e) Salmonella spp. and E. coli producing the following enzymes: (i) Extended Spectrum β‐Lactamases (ESBL); (ii) AmpC β‐Lactamases (AmpC); (iii) Carbapenemases (CP). Therefore, during 2021, AMR data were collected from the bacteria listed above. It seems relevant to notice that the collection of AMR data from Campylobacter coli isolates was not compulsory in 2020. Despite this, some countries reported AMR data related to Campylobacter coli.
Countries can also report AMR data from other agents of public health importance such as methicillin‐resistant Staphylococcus aureus (MRSA). According to Commission Implementing Decision(EU) 2020/1729 the monitoring and reporting of AMR may also cover indicator commensal Enterococcus faecalis (E. faecalis) and Enterococcus faecium (E. faecium).
A scientific report published by EFSA in 2012 included technical specifications on the harmonised monitoring and reporting of antimicrobial resistance in methicillin‐resistant Staphylococcus aureus (MRSA) in food‐producing animals and food (EFSA, 2012 (link)). Detailed rules were specified for harmonised monitoring and reporting on the prevalence of resistant microorganisms in food‐producing animals and food, in particular as regards the microorganisms to be included, the origin of the isolates of the microorganisms, the number of isolates to be tested, the antimicrobial susceptibility tests to be used, the specific monitoring of MRSA and ESBL‐ or AmpC‐producing bacteria and the collection and reporting of the data. Comparison between human data and data from food‐producing animals and food sector was ensured by involvement of ECDC.
The Commission Implementing Decision (EU) 2020/1729 specifies that the monitoring and reporting of AMR shall cover the following food‐producing animal populations and food: (a) broilers; (b) laying hens; (c) fattening turkeys; (d) bovine animals under 1 year of age; (e) fattening pigs; (f) fresh meat from broilers; (g) fresh meat from turkeys; (h) fresh meat from pigs; (i) fresh meat from bovine animals. This European Commission Decision indicates the sampling frequency for MSs to carry out the AMR monitoring and reporting in accordance with the following rotational system: (a) In the years 2021, 2023, 2025 and 2027: in fattening pigs, bovine animals under 1 year of age, pig meat and bovine meat. (b) In the years 2022, 2024 and 2026: in laying hens, broilers, fattening turkeys and fresh meat derived from broilers and turkeys.
Therefore, following relevant EU legislation AMR data presented in this Report were collected from poultry populations and derived meat thereof in 2020 and from pigs and from bovines under 1 year of age in 2021.
The Commission Implementing Decision (EU) 2013/652 and the Commission Implementing Decision(EU) 2020/1729 lay down detailed rules for sampling design and sample size as well as for antimicrobial susceptibility testing for the different bacteria. These European Commission Decisions indicate the analytical methods for detection and antimicrobial susceptibility testing that shall be performed by the laboratories referred to in Article 3(2). AMR testing shall be performed by using the broth microdilution method according to the reference method ISO 20776‐1:2019.
For AMR testing, isolates were obtained through harmonised national programs. The broth microdilution testing method was widely used for susceptibility testing following EU legislation.
On November 17, 2020, the European Commission laid down the new technical specifications in Commission Implementing Decision (EU) 2020/1729 and repealed Commission Implementing Decision(EU) 2013/652. The new legislation came into effect on 1 January 2021, and updates technical specifications for harmonised AMR monitoring and reporting to include the monitoring of AMR in derived meat sampled at border control posts, the testing of new substances. The new legislation also authorises WGS as an alternate method to phenotypic testing for AMR monitoring. The new rules apply until December 2027.
Resulting quantitative32 isolate‐based data were reported to EFSA and considered for this report. Resistance was interpreted using EUCAST ECOFF values (see text box below for further information). The antimicrobials incorporated in this report were selected based on their public health relevance and as representatives of different antimicrobial classes. Data on methicillin resistant Staphylococcus aureus (MRSA) and other microorganisms apart from those required by legislation were reported on a voluntary basis.
Full text: Click here
Publication 2023
Animal Population Groups Animals Bacteria Campylobacter coli Campylobacter jejuni carbapenemase Cattle Compulsive Behavior Drug Resistance, Microbial Enterococcus faecalis Enterococcus faecium Enzymes Escherichia coli Europeans Feeds, Animal Food Fowls, Domestic Homo sapiens Meat Meleagridinae Methicillin-Resistant Staphylococcus aureus Microbicides Phenotype Population Group Pork Meat Salmonella Susceptibility, Disease Sus scrofa
Plasmid pFBP1 (previously named pWD-CpFBP1) was described in [23 (link)]. Plasmid pFBA1 contains, in place of the FBP1 sequence in pFBP1, the C. reinhardtii FBA1 coding sequence (nuclear), gene synthesized (Genscript Biotech Corporation, Piscataway, NJ, USA) to be codon optimized for the C. reinhardtii chloroplast and to contain a C-terminal myc tag, flanked by SfoI and MscI restriction sites. Plasmid pVHH contains a similarly codon-optimized fragment encoding a VHH antibody targeting the flagellum of the food poisoning agent Campylobacter jejuni [24 (link)], but also a 38 amino acid N-terminal Streptavidin-Binding Peptide (SBP) and C-terminal myc tag. Plasmid p-423 (contains the aadA gene conferring spectinomycin resistance [25 (link)]) was obtained from the Chlamydomonas Resource Center (St. Paul, MN, USA).
The pFBP1-cs-ts-atpB vector was generated by combining gene-synthesized and existing gene fragments, as described below, and schematic depiction of the strategy for generating this and other synthetic operons is provided in Figure 1A. A 1614-bp DNA fragment was gene synthesized (Genscript) to contain the 55-bp spacer sequence of the Synechococcus elongatus apc operon that separates the stop codon of the apcA gene and the start codon of the apcB gene and the 47-bp Nicotiana tabacum rps/rpl operon spacer that separates the rps19 stop codon from the rpl22 start codon, and the 1470-bp C. reinhardtii atpB coding sequence. The cyanobacterial and tobacco spacer sequences were separated by a 9-bp sequence containing a start codon and SfoI restriction site, and that operon cassette was preceded by SnaBI and PmeI restriction sites (surrounding a stop codon) at the 5′ end to permit joining of either operon spacer with downstream atpB gene to an upstream gene through blunt-end cloning. The atpB coding region was synthesized to contain a StuI restriction site immediately following its start codon and an MscI restriction site immediately following its final codon. The gene-synthesis fragment was digested with SnaBI and MscI to liberate a 1608-bp blunt-ended fragment that was ligated into MscI-digested pFBP1 to generate p-FBP1-cs-ts-atpB. p-FBP1-cs-ts-atpB was used to generate the nine chloroplast expression vectors tested in this study, which contain different combinations of the FBP1, atpB, FBA1, and VHH genes connected by cyanobacterial and/or tobacco chloroplast operon spacers as described below.
pFBP1-cs-atpB and pFBP1-ts-atpB, which contain the FBP1 and atpB genes connected by the cyanobacterial spacer or the tobacco spacer, respectively, were generated as follows. pFBP1-cs-ts-atpB was digested with restriction enzymes SfoI and StuI (Thermo Fisher Scientific, Waltham, MA, USA) and then religated to produce pFBP1-cs-atpB, and it was digested with PmeI and SfoI and then religated to produce pFBP1-ts-atpB.
pFBP1-cs-VHH and pFBP1-ts-VHH, which contain the FBP1 and VHH genes connected by the cyanobacterial spacer or the tobacco spacer, respectively, were generated as follows. First, pFBP1-cs-atpB was digested with SfoI and MscI to remove the fragment containing the atpB gene and cyanobacterial spacer, and the remaining 9.355-kb vector fragment from this digest was ligated with the 1005-bp coding sequence fragment of the VHH gene derived from a Eco47III and MscI digest of vector pVHH; the completed expression vector was named pFBP1-cs-VHH. pFBP1-ts-VHH was generated by ligating the Eco47III-MscI VHH fragment into the vector fragment produced by StuI and MscI digestion of pFBP1-ts-atpB.
pFBP1-cs-FBA and pFBP1-ts-FBA, which contain FBP1 and FBA1 genes connected by the cyanobacterial spacer or the tobacco spacer, respectively, were generated as follows. pFBP1-cs-FBA was produced by ligating the 1170-bp coding sequence fragment of FBA1 that was liberated by digesting pFBA1 with SfoI and MscI into the vector fragment derived from a digest of pFBP1-cs-atpB with StuI and MscI. Similarly, pFBP1-ts-FBA was generated by ligating the 1170-bp SfoI-MscI FBA1 fragment into the vector fragment derived from a StuI + MscI digest of pFBP1-ts-atpB.
Expression vectors pFBP1-cs-FBA-cs-atpB, pFBP1-cs-FBA-ts-atpB, and pFBP1-ts-FBA-ts-atpB were generated as follows. The 1542-bp fragment containing the cyanobacterial spacer and atpB gene coding sequence was liberated by digesting pFBP1-cs-atpB with PmeI and MscI, then was ligated into the vector fragment derived from an MscI digest of pFBP1-cs-FBA to generate pFBP1-cs-FBA-cs-atpB. Similarly, the 1532-bp SfoI-MscI fragment from pFBP1-ts-atpB was ligated into MscI-digested pFBP1-cs-FBA to produce pFBP1-cs-FBA-ts-atpB. Finally, the 1532-bp SfoI-MscI fragment from p-FBP1-cs-ts-atpB containing the tobacco operon spacer and atpB coding sequence was ligated into MscI-digested pFBP1-ts-FBA, to generate pFBP1-ts-FBA-ts-atpB. All final constructs were verified by diagnostic restriction digestions and sequencing (primers displayed in Table 1) to verify expected fragment sizes, to determine that no unintended sequence changes had occurred during cloning steps, and to verify that insert fragments were all in correct orientation.
Full text: Click here
Publication 2023
Amino Acids Anabolism Campylobacter jejuni Chlamydomonas Chloroplasts Cloning Vectors Codon Codon, Initiator Codon, Terminator Cyanobacteria Diagnosis Digestion DNA Restriction Enzymes Encephaloclastic Proliferative Vasculopathy Episodic Ataxia, Type 2 Flagella Genes Nicotiana Nicotiana tabacum Oligonucleotide Primers Open Reading Frames Operon Plasmids RPL22 protein, human RPS19 protein, human Spectinomycin streptavidin-binding peptide Synechococcus elongatus VHH Immunoglobulin Fragments
We performed antimicrobial susceptibility testing (AST) on 5 Campylobacter coli and 39 Campylobacter jejuni isolates recovered from the litter of broiler chicks following the National Antimicrobial Resistance Monitoring System (NARMS) protocol for Gram-negative bacteria. The following antimicrobials were tested: Azithromycin, Ciprofloxacin, Clindamycin, Erythromycin, Florfenicol, Gentamicin, Nalidixic Acid, Telithromycin and Tetracycline. Antimicrobial susceptibility of Campylobacter isolates was determined using the Sensititre semi-automated system (Thermo Fisher Scientific, Kansas City, KS) according to manufacturer’s instructions. Briefly, bacterial suspensions equivalent to a 0.5 McFarland suspension were prepared, aliquoted into a CAMPY panel and incubated at 42°C for 24 h under microaerobic conditions. Minimum inhibitory concentrations were determined and categorized as resistant according to breakpoints based on epidemiological cut-off values as used by the National Antimicrobial Resistance Monitoring System (NARMS; https://www.fda.gov/media/108180/download).
Publication Preprint 2023
Azithromycin Bacteria Campylobacter Campylobacter coli Campylobacter jejuni Ciprofloxacin Clindamycin Erythromycin florfenicol Gentamicin Gram Negative Bacteria Hartnup Disease Microbicides Minimum Inhibitory Concentration Nalidixic Acid Susceptibility, Disease telithromycin Tetracycline
Antibiotic susceptibility was tested by the disk diffusion method (Kirby Bauer). Antibiotic test disks were placed on agar plates with Mueller Hinton agar supplemented with 5% horse blood (MHF) inoculated with an A. butzleri bacterial suspension (MacFarland: 0.5). The test agar plates were incubated at 42°C under microaerophilic conditions for 24 h. The microaerophilic atmosphere was generated using a Whitley jar gassing system (Don Whitley Scientific Limited, Bingley, UK). Bacterial isolates with insufficient growth after 24 h were re-incubated, and the inhibition zone was measured after a total of 40–48 h. Since there are no breakpoints defined for Arcobacter neither according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) nor the Clinical & Laboratory Standards Institute (CLSI), the zone diameter was simply measured and an epidemiological cut-off (Ecoff) value determined on the basis of all tested isolates (for the definition of Ecoff values, see results). Isolates were tested for tetracycline (TE30), ciprofloxacin (CIP5), erythromycin (E15), gentamicin (CN10), and ampicillin (AMP10). Antimicrobial test discs were obtained from Oxoid/Thermo Fisher Scientific (Wesel, Germany). The laboratory work was carried out in a laboratory accredited according to DIN EN ISO 15189. The quality control strains used for resistance testing by agar diffusion were Campylobacter jejuni ATCC 33560 for the antibiotic test discs CIP5 (5 µg ciprofloxacin per disc), E15 (15 µg erythromycin per disc), and TE30 (30 µg tetracycline per disc), Pseudomonas aeruginosa ATCC 27853 for CN10 (10 µg gentamicin per disc), and Enterococcus faecalis ATCC 29212 for AMP10 (10 µg ampicillin per disc). Resistance to the three classes of antibiotics comprised of tetracyclines, fluoroquinolones, and macrolides was defined as multidrug resistance (MDR).
Full text: Click here
Publication 2023
Agar Ampicillin Antibiotic Resistance, Microbial Antibiotics Arcobacter Atmosphere Bacteria Blood Campylobacter jejuni Ciprofloxacin Clinical Laboratory Services Diffusion Enterococcus faecalis Equus caballus Erythromycin Europeans Fluoroquinolones Gentamicin Hartnup Disease Macrolides Microbicides Multi-Drug Resistance Pseudomonas aeruginosa Psychological Inhibition Strains Susceptibility, Disease Tetracycline Tetracyclines

Top products related to «Campylobacter jejuni»

Sourced in United States
Campylobacter jejuni is a bacterial strain available from the American Type Culture Collection (ATCC). It is a Gram-negative, microaerophilic, spiral-shaped bacterium that is widely used in research and laboratory settings.
Sourced in United Kingdom, United States, France, Germany
The CampyGen is a compact and self-contained gas generator that produces a microaerophilic atmosphere suitable for the culture of Campylobacter species. It is designed to provide a controlled environment for the growth of these fastidious organisms in the laboratory setting.
Sourced in United States, China, Germany, United Kingdom, France, Portugal, Canada, Brazil, Italy
Escherichia coli is a bacterium that is commonly used in laboratory settings. It serves as a model organism for microbiology and molecular biology research. Escherichia coli can be cultivated and studied to understand fundamental cellular processes and mechanisms.
Sourced in Germany, United Kingdom
CampyGen gas packs are a laboratory product designed to create an anaerobic atmosphere for the cultivation of Campylobacter species. The gas packs generate a controlled mixture of gases, including hydrogen and carbon dioxide, to support the growth of these microaerophilic bacteria.
Sourced in United Kingdom, United States, Italy, Germany, Australia, Canada, Ireland, Czechia
Mueller-Hinton broth is a culture medium used for the growth and susceptibility testing of bacteria. It provides the necessary nutrients for the cultivation of a wide range of microorganisms. The broth is formulated to support the growth of non-fastidious bacteria and is commonly used in antimicrobial susceptibility testing.
Sourced in United Kingdom, Germany
Campylobacter blood-free selective agar base is a culture medium used for the isolation and identification of Campylobacter species from clinical and non-clinical samples. It is a selective and differential agar that supports the growth of Campylobacter while inhibiting the growth of other bacteria.
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United Kingdom, Germany, United States
Horse blood is a biological sample that can be used for various laboratory applications. It serves as a source of biomolecules, cells, and other components that are essential for scientific research and analysis.
Sourced in United Kingdom, United States, Australia, Italy, Spain, Germany, Canada, Belgium
Buffered peptone water is a general-purpose microbiological culture medium used for the enrichment and recovery of a wide range of microorganisms. It provides a buffered environment and peptone as a source of nutrients to support the growth of microbes.
Sourced in United States, China, United Kingdom, Germany, Brazil, Malaysia, Italy, Portugal
Staphylococcus aureus is a bacterial strain available in the American Type Culture Collection (ATCC) product portfolio. It is a Gram-positive, spherical-shaped bacterium commonly found in the human nasal passages and on the skin. This strain is widely used in research and laboratory settings for various applications.

More about "Campylobacter jejuni"

Campylobacter jejuni (C. jejuni) is a spiral-shaped, microaerophilic, gram-negative bacterium that is a leading cause of gastroenteritis worldwide.
It is commonly found in the gastrointestinal tract of many animals, including poultry, cattle, and wild birds.
Infection with C. jejuni can lead to diarrhea, abdominal pain, and fever, and in some cases, can trigger the development of Guillain-Barré syndrome, a rare neurological disorder.
Researching effective protocols and methods for the detection, identification, and management of C. jejuni is crucial for public health and food safety.
CampyGen, a gas pack system, can be used to create a microaerophilic environment for the growth of C. jejuni.
Mueller-Hinton broth and Campylobacter blood-free selective agar base are commonly used media for culturing and isolating this pathogen.
Fetal bovine serum (FBS) and horse blood can also be used to supplement growth media.
Buffered peptone water is a common diluent used for preparing samples for C. jejuni detection.
Staphylococcus aureus, a gram-positive bacterium, is sometimes used as a control organism in C. jejuni research and testing.
PubCompare.ai offers a powerful tool to streamline this research by leveraging AI-driven protocol comparisons, helping scientists identify the most reproducible and accurate approaches from literature, pre-prints, and patents.
This tool can optimize Campylobacter jejuni research by facilitating the identification of the best protocols and methods, ultimately enhancing public health and food safety.